
-
XBiotech NasdaqGS:XBIT XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Location: 5217 Winnebago Lane, 8201 E Riverside Dr Ste 100, Austin, TX, 78744, United States | Website: https://www.xbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-63.21M
Cash
155.9M
Avg Qtr Burn
-7.62M
Short % of Float
4.53%
Insider Ownership
35.07%
Institutional Own.
14.83%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Hutrukin Details Brain disease, Ischemic stroke | Phase 2 Update | |
Natrunix + Methotrexate (MTX) Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Update | |
Natrunix w/ ON+5FU+LV Details Cancer, Pancreatic cancer | Phase 1/2 Update | |
Natrunix + trifluridine/tipiracil Details Cancer, Colorectal cancer | Phase 1 Update | |
514G3 Details Bacterial infection, Methicillin-resistant staphylococcus aureus | Failed Discontinued | |
Bermekimab Details Skin disease/disorder | Failed Discontinued | |
Bermekimab Details Skin disease/disorder, Hidradenitis suppurativa | Failed Discontinued |